| 1 |
ROS-Targeting Nanozyme Drug Candidate for 2nd Degree Burn Wounds |
| Others-Synth. |
2nd-Degree Burn Wound |
2nd-Degree Burn Wound |
Preclinical |
HTnB Inc. |
RS-2026-25502877 |
|
| 2 |
Phase 1 Clinical Trial IND Clearance for the Osteoarthritis Therapeutic PRT101 Through Preclinical Studies, Toxicity Evaluation, and CMC Establishment |
| Small molecules |
Osteoarthritis |
SOX9 |
Preclinical |
PROTEINA |
RS-2026-25501950 |
|
| 3 |
Development of novel small molecule for CKD treatment |
| Small molecules |
CKD |
**** |
Preclinical |
Yuhan / R&D Institute |
RS-2025-25451385 |
|
| 4 |
A Study on Global Clinical Approval of Exosome-Based Therapeutics Loaded with Anti-inflammatory Proteins for Treatment of ***** |
| Other-Bio. |
**** |
**** |
Preclinical |
ILIAS Biologics Inc. |
RS-2025-25444945 |
|
| 5 |
Non-clinical development of ARBM-101 as an innovative Wilson's disease drug |
| rProtein |
Wilson disease |
ATP7B |
Preclinical |
ARBORMED |
RS-2025-02213496 |
|
| 6 |
Exosome-Based Therapy for Chronic Kidney Disease: Preclinical and IND-Enabling Studies |
| Other-Bio. |
CKD |
Super repressor IκB |
Preclinical |
ILIAS Biologics Inc. |
RS-2025-02073027 |
|
| 7 |
Nonclinical Development of Enhanced Safety Macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging |
| Others-Synth. |
MRI liver imaging |
Gadolinium Based Liver-specific Contrast Agent |
Preclinical |
PharmGen Science, Inc. |
RS-2024-00462636 |
|
| 8 |
Development of TMAU Treatment through FDA Rare Disease Designation and IND Approval |
| Other-Bio. |
Trimethylaminuria |
TMA |
Preclinical |
BioMe, Inc. |
RS-2024-00443597 |
|
| 9 |
Development of osteoarthritis drug with a novel mechanism of inflammasome blockade |
| Small molecules |
Osteoarthritis |
Caspase |
Preclinical |
Innovo Therapeutics, Inc. |
RS-2023-00282719 |
|
| 10 |
Pre-clinical studies of DMOAD candidate DRT-101 for Osteoarthritis |
| rProtein |
Degenerative arthritis |
bmp7 |
Preclinical |
Darnatein |
RS-2023-00258278 |
|
| 11 |
Development of EFL.1101, a topical anticholinergic agent, for the Treatment of Hyperhidrosis |
| Small molecules |
Hyperhidrosis |
Muscarinic M3 |
Preclinical |
eFlask |
RS-2023-00258121 |
|
| 12 |
Pre-clinical study and IND application of PAT101, a tophaceous gout treatment, using SelecAllTM technology |
| rProtein |
Gout |
Uric Acid |
Preclinical |
ProAbTech |
RS-2023-00219125 |
|
| 13 |
A novel GFRA1 agonist, JW0061 development for androgenic alopecia treatment |
| Small molecules |
Androgenetic alopecia |
GFRA1 |
Preclinical |
JW Pharmaceutical |
RS-2023-00217372 |
|
| 14 |
Multi-modal cell-penetrating peptide for diabetic foot ulcer |
| rProtein |
Diabetic foot ulcer |
pre-let7 miRNA |
Preclinical |
StemMeditech Inc. |
RS-2022-00165887 |
|
| 15 |
Nonclinical Drug Development of anti-achondroplasia therapy for activated FGFR3 inhibition with NPR-B-Targeting Peptide |
| rProtein |
Achondroplasia |
NPR-B |
Preclinical |
Peptron, Inc |
HN21C1247 |
|